Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CK-303
- Development stage
- Preclinical
- Lead developer
- Checkpoint Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
CK-303 is a fully human monoclonal antibody targeting carbonic anhydrase IX (CAIX), a cell-surface enzyme that is highly expressed in over 85% of renal cell carcinoma (RCC) cases but has very limited expression in normal tissues. Developed by Checkpoint Therapeutics through a license from the Dana-Farber Cancer Institute, CK-303 is designed to bind specifically to CAIX-expressing tumor cells and induce cell death via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug is currently in preclinical development for the treatment of RCC and other CAIX-positive solid tumors, with potential for use in combination with other immunotherapies such as anti-PD-L1 or anti-GITR antibodies.
- Other names
- anti-CAIX monoclonal antibody
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on CK-303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CK-303.